Unique selling points
Mosaiques' proteome analysis has secured a distinctive position in the global market for clinical applications, especially in diagnostics, therapy assessment, and drug development. This success is driven by the use of reliable and reproducible clinical proteomic biomarkers, along with a proprietary database.
- Comprehensive Mapping of the Urine Proteome: Mosaiques has precisely mapped the urine proteome, identifying over 24,000 distinct proteins and peptides detectable in a single sample. This is made possible through Mosaiques' unique database, which contains over 85,000 datasets accumulated over 20 years. No other provider has a comparable database or as detailed an understanding of urine peptides and proteins, including their distribution.
- Proven Validity of Mosaiques' Technology: The reliability of Mosaiques' technology has been demonstrated in
over 100 studies and more than 400 scientific publications. This includes the reproducibility of sample preparation, the robustness of the analytical platform, and the consistency of data evaluation. This strong foundation allows for seamless comparison of data from samples measured 20 years ago with current data. The exceptional durability and robustness of Mosaiques' technology, recognized among others by a
'Letter of Support' from the US-FDA, ensures precise and reproducible analysis of individual proteome data, enabling detection of changes in the proteome over time, in response to therapies, or due to lifestyle factors. This valid analysis forms the basis for identifying effective drugs by targeting specific proteins.
- Support Beyond Measurement: Unlike other providers, Mosaiques, along with protexam and xken-health, offers much more than the mere measurement of proteins and peptides in urine. Doctors and patients are not left to interpret isolated values on their own. Instead, specific disease risks are identified with a high degree of sensitivity and specificity, based on extensive clinical studies, a process necessary for securing marketing authorizations.
- Advanced Data Analysis and AI: Mosaiques identifies proteins and peptides in urine that show significant changes in specific diseases and integrates these changes into a classification factor. This is achieved using AI and specialized algorithms that operate within a high-dimensional data space. These classification factors typically rely on hundreds of different proteins and peptides, with their individual distribution in each sample analysed and combined using proprietary algorithms. To reach this level of precision, a robust database and detailed knowledge of disease-specific changes are essential—knowledge that Mosaiques can offer based on its vast number of measurements and reliable technology.
- Comprehensive Disease Insight: Mosaiques' extensive proprietary database enables the identification of disease-related changes and their relationship to disease severity, progression, and therapeutic impact. A single sample can be used to assess multiple diseases and their associated comorbidities simultaneously.
- In-Depth Proteome Analysis: Mosaiques does not merely offer a 'basic proteome analysis.' Instead, a comprehensive evaluation of specific disease markers and risks is provided. This approach differs significantly from other companies in the proteome analysis space, whose technologies generally lack the capability to deliver such detailed and specific insights. Mosaiques also prioritizes patient benefits, considering other diseases in the process.
These distinctive features of Mosaiques' technology enable the decoding of the personalized proteome for the first time, allowing for the precise identification of disease-specific proteome biomarkers.
Thanks to its exceptional data and study results, Mosaiques' patented proteome analysis technology has led to the approval of its in-vitro diagnostic (IVD) tests in Germany and Europe.
By combining this technology with its extensive proteome database, which incorporates disease progression and clinical findings, Mosaiques can predict drug response 'in-silico.' No other company globally provides a comparable service.
Comparison of Mosaiques' technologies with others:
▶ Clinical Relevance and Consistency: The value and clinical benefit of Mosaiques’ comprehensive protein analysis—representing the ‘handprint’ of an individual’s proteome—has been demonstrated through numerous clinical studies. A key factor in proving this benefit is Mosaiques' proprietary method, which consistently delivers reproducible results and is permanently controlled using appropriate standard (urine) sample. Many companies offering protein or proteome analysis do not meet this basic requirement.
▶ Scope of Proteome Analysis: Reputable providers of proteome analysis typically focus on a pre-specified, limited number of proteins or protein fragments and do not offer comprehensive clinical testing. The further a method strays from directly analysing the specific, naturally occurring proteins or peptides, the higher the likelihood of inconsistencies, making it difficult to reproduce results. Published studies globally recognize urine as the most stable and informative medium for analysis because, unlike blood, among others because it is generally not affected by proteolytic enzymes that degrade proteins.
▶ Extensive Published Scientific Evidence: Mosaiques has established a high standard of transparency by publishing its scientific findings in leading peer-reviewed journals. This contrasts with several proteomic approaches that have garnered public attention despite lacking sufficient clinical or scientific validation, often making misleading claims that have yet to demonstrate any clinical benefit in peer-reviewed studies.
Details on Mosaiques’ unique technological position:
- Mosaiques' proteome analysis: Mosaiques analyses proteins and peptides in their unmodified form and measures their concentration directly in their original state using mass spectrometry. In contrast, other mass spectrometry techniques measure (typically tryptic) fragments, generated from the proteins in the sample. The amount of these peptides is used to infer the original protein present, although results may vary depending on the fragment analysed. Importantly, modifications to proteins that are critical to their function are usually not considered in these methods. More information can be found here.
- Limitations of Non-Mass Spectrometry Techniques: Techniques that do not rely on mass spectrometry, such as those using antibodies or aptamers, attempt to measure protein concentrations by binding to a target protein, though this binding is often less specific. These methods typically provide no information about post-translational protein modifications. It is often unclear whether the target or a similar protein has been bound. This uncertainty may explain why inconsistent results are often obtained when the same sample is analysed using different methods, even though identical results would theoretically be expected. Additionally, these non-mass spectrometry techniques are generally unsuitable for urine analysis due to interfering factors that disrupt their analytical platforms.
- Multi-Disease Analysis from a Single Sample: A further key advantage of Mosaiques' technology is its ability to extract information about multiple diseases from a single sample and dataset. Thanks to the vast data on thousands of peptides and proteins in each sample, one dataset can be simultaneously analyzed for conditions such as kidney disease, cardiovascular disease, various types of tumors, etc., without requiring additional samples.
- Advancement in Drug Development: Mosaiques' comprehensive database and insights into specific drug mechanisms enable the identification of molecular pathologies that inform the development of new therapeutics. This knowledge is used to design targeted treatments, making drug development more precise, less risky, and more cost-effective, thereby revolutionizing the process.